Abstract: The present disclosure provides, among other things, a method of cryopreserving and thawing cells that results in the thawed cells having high cellular viability and functionality post-thawing. In some embodiments, a large-scale method of cryopreserving cells is provided, the method comprising: (a) contacting the cells with a cryopreservation medium; (b) cooling the cells to ?80° C. at a controlled rate to minimize latent heat of fusion; and (c) storing the cells in liquid nitrogen vapor phase, thereby cryopreserving the immune cells.

Abstract: The present disclosure provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: dimethyl sulfoxide (DMSO), disaccharide, human serum, and IL-7 and/or IL-15. The present disclosure also provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: between about 1 w/v % and 10 w/v % dimethyl sulfoxide (DMSO), between about 0.25 w/v % and 5 w/v % disaccharide, and between about 10 w/v % and 90 w/v % human serum. The present disclosure also provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: between about 1 w/v % and 10 w/v % dimethyl sulfoxide (DMSO), between about 0.25 w/v % and 5 w/v % disaccharide, and between about 0.5 w/v % and 30 w/v % human serum albumin.

Abstract: The present disclosure provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: dimethyl sulfoxide (DMSO), disaccharide, human serum, and IL-7 and/or IL-15. The present disclosure also provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: between about 1 w/v % and 10 w/v % dimethyl sulfoxide (DMSO), between about 0.25 w/v % and 5 w/v % disaccharide, and between about 10 w/v % and 90 w/v % human serum. The present disclosure also provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: between about 1 w/v % and 10 w/v % dimethyl sulfoxide (DMSO), between about 0.25 w/v % and 5 w/v % disaccharide, and between about 0.5 w/v % and 30 w/v % human serum albumin.

Abstract: The present disclosure provides a thermoplastic polyurethane obtained from the reaction of a reaction mixture comprising (i) a polyisocyanate comprising isophorone diisocyanate, (ii) a polyol component comprising an aliphatic polyester polyol or an aliphatic polyether polyol, and (iii) a chain extender. The thermoplastic polyurethane may be used in a variety of applications, such as in automotive, electronic device and consumer product applications.

Abstract: The present disclosure provides, among other things, a method for efficiently producing natural killer cells from induced pluripotent cells. The method includes the steps of: (I) culturing pluripotent stem cells in a culture medium to produce CD56+/CD3? immune cells.

Abstract: A class of benzoxazinone derivatives and a preparation method therefor, specifically related to a compound shown in formula (II), or a stereoisomer or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides, among other things, a cryopreservation medium comprising a cryoprotectant, an albumin, a disaccharide and a non-pyrogenic and isotonic crystalloid solution. The disclosure also provides, among other things, a cryopreservation medium for cryopreserving immune cells, the medium comprising: human serum albumin (HSA), sodium chloride, sodium gluconate, sodium acetate trihydrate, potassium chloride, magnesium chloride, dimethyl sulfoxide (DMSO), and a trehalose. The present disclosure also provides, a method of cryopreserving immune cells, transporting and subsequently administering such immune cells to a patient in need thereof.

Abstract: In some implementations, an optimization system may obtain health information identifying different measures of health of an asset. The health information identifies end of life information regarding an end of life curve of the asset and an effective age of the asset. The optimization system may determine, based on the health information, a hazard curve for the asset. The hazard curve indicates a predicted failure rate of the asset over a period of time. The optimization system may provide the hazard curve and the effective age of the asset as inputs to an optimization model. The optimization system may use the optimization model to determine a particular time for replacing the asset, wherein the particular time is determined based on the hazard curve and the effective age. The optimization system may cause the asset to be replaced at the particular time.

Abstract: An aliphatic thermoplastic polyurethane resin composition comprising: (a) an isocyanate compound; (b) an isocyanate reactive compound; (c) a chain extender compound; and (d) one or more additives; and wherein after the thermoplastic polyurethane resin composition is formed into an aliphatic thermoplastic polyurethane film having a thickness of 0.1 mm, the aliphatic thermoplastic polyurethane film has: (x) a modulus of at least 800 MPa at 25° C. and (y) a haze value of less than 2%.

Abstract: The present disclosure provides, among other things, a cryopreservation medium comprising a cryoprotectant, an albumin, a disaccharide and a non-pyrogenic and isotonic crystalloid solution. The disclosure also provides, among other things, a cryopreservation medium for cryopreserving immune cells, the medium comprising: human serum albumin (HSA), sodium chloride, sodium gluconate, sodium acetate trihydrate, potassium chloride, magnesium chloride, dimethyl sulfoxide (DMSO), and a trehalose. The present disclosure also provides, a method of cryopreserving immune cells, transporting and subsequently administering such immune cells to a patient in need thereof.

Abstract: In some implementations, an optimization system may obtain health information identifying different measures of health of an asset. The health information identifies end of life information regarding an end of life curve of the asset and an effective age of the asset. The optimization system may determine, based on the health information, a hazard curve for the asset. The hazard curve indicates a predicted failure rate of the asset over a period of time. The optimization system may provide the hazard curve and the effective age of the asset as inputs to an optimization model. The optimization system may use the optimization model to determine a particular time for replacing the asset, wherein the particular time is determined based on the hazard curve and the effective age. The optimization system may cause the asset to be replaced at the particular time.

Abstract: The present disclosure provides recombinant antigen presenting cells and methods of use thereof in the culture and expansion of immune cells ex vivo. In some aspects, immune cells expanded through co-culture of the recombinant antigen presenting cells disclosed herein are administered to a subject to treat a disease or condition in the subject, e.g., to treat a cancer.

Abstract: The present application provides cord blood-derived natural killer (CB-NK) cells engineered to express chimeric receptors that target ADGRE2. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Abstract: The present disclosure provides, among other things, a method for efficiently producing a cell population enriched in Natural Killer cells (NK cells) from induced pluripotent cells.

Abstract: The present disclosure relates to systems and methods for flow-through separation of paramagnetic particle-bound cells in a cell suspension containing both bound and unbound cells as well as systems and methods for removing paramagnetic particles from paramagnetic particle-bound cells or from a cell suspension with unbound cells. It further relates to a flow-through magnetic separation/debeading module and a flow-through spinning membrane debeading module.

Abstract: The present disclosure provides, among other things, a method of cryopreserving and thawing cells that results in the thawed cells having high cellular viability and functionality post-thawing. In some embodiments, a large-scale method of cryopreserving cells is provided, the method comprising: (a) contacting the cells with a cryopreservation medium; (b) cooling the cells to ?80° C. at a controlled rate to minimize latent heat of fusion; and (c) storing the cells in liquid nitrogen vapor phase, thereby cryopreserving the immune cells.

Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.

Abstract: A thermoplastic polyurethane resin composition comprising: a thermoplastic polyurethane resin; an ultraviolet absorber package comprising a benzotriazole compound (UVA1), and a triazine compound (UVA2) wherein the mass ratio of UVA1 to UVA2 is from 1:1 to 3:1; optionally, a hindered amine light stabilizer and/or an antioxidant compound; and wherein the thermoplastic polyurethane resin composition has a maximum ultraviolet transmittance of ?3% in the wavelengths between 280 nm and 365 nm and an ultraviolet transmittance of ?6% in the wavelengths between 365 nm and 370 nm when the thermoplastic polyurethane resin is formed into a film having a thickness of 6 mils and wherein the cumulative weight % of UVA1 and UVA2 in the polyurethane resin composition ranges from 0.5 wt % to 0.85 wt % based on the total weight of the polyurethane resin composition.

Abstract: The present disclosure relates to a thermoplastic polyurethane (TPU) based polymer electrolyte composition hosting an ion conductive salt in the presence of a plasticizer.

Abstract: Methods, apparatus, computer program products Geohash-based traffic management are provided. The method comprises receiving, by one or more processing units, respective operating status data of one or more vehicles travelling within a Geohash cell; generating, by one or more processing units, one or more service messages based on the received respective operating status data according to one or more service specifications; and providing, by one or more processing units, at least one of the one or more service messages responsive to a request from a vehicle travelling within the Geohash cell.